PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC9065177::ACT052871

MP

Evidence text

Paper-level observation

These stapled peptides were evaluated for cytotoxicity in the CRC cell line CT26 in vitro, IC50 values ranged from 1.11 μM to 9.32 μM. These stapled MP derivatives exhibited either enhanced or same anti-CRC activity, in comparison to the parent MP.
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Cytotoxic
Measure
other
Comparator
=
Raw observation
IC50 values ranged from 1.11 μM to 9.32 μM for stapled peptides; MP IC50 not explicitly given but stated stapled derivatives exhibited enhanced or same anti-CRC activity compared to parent MP
Normalized measurement
=0 µM
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
CT26
Assay method
Not reported by source
Sequence
INLKALAALAKKIL
Standardization
ready simple

Source publication

Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.

Theranostics · 2022

DOI 10.7150/thno.71129 PMC9065177
Parent mention Integrated peptide

Related peptide identities

PEPDIA-PLP-003679PEPDIA-INT-081761

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.